| Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good … SS Bielack, S Smeland, JS Whelan, N Marina, G Jovic, JM Hook, ... Journal of Clinical Oncology 33 (20), 2279-2287, 2015 | 397 | 2015 |
| EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment JS Whelan, SS Bielack, N Marina, S Smeland, G Jovic, JM Hook, M Krailo, ... Annals of oncology 26 (2), 407-414, 2015 | 346 | 2015 |
| Departmental experience and lessons learned with accelerated introduction of telemedicine during the COVID-19 crisis AE Loeb, SS Rao, JR Ficke, CD Morris, LH Riley III, AS Levin JAAOS-Journal of the American Academy of Orthopaedic Surgeons 28 (11), e469-e476, 2020 | 336 | 2020 |
| NCCN guidelines insights: bone cancer, version 2.2017 JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ... Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 2017 | 276 | 2017 |
| Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care SS Nathan, JH Healey, D Mellano, B Hoang, I Lewis, CD Morris, ... Journal of clinical oncology 23 (25), 6072-6082, 2005 | 224 | 2005 |
| Addition of pamidronate to chemotherapy for the treatment of osteosarcoma PA Meyers, JH Healey, AJ Chou, LH Wexler, PR Merola, CD Morris, ... Cancer 117 (8), 1736-1744, 2011 | 197 | 2011 |
| Endoprosthetic treatment is more durable for pathologic proximal femur fractures M Steensma, PJ Boland, CD Morris, E Athanasian, JH Healey Clinical Orthopaedics and Related Research® 470, 920-926, 2012 | 158 | 2012 |
| Addition of vincristine and irinotecan to vincristine, dactinomycin, and cyclophosphamide does not improve outcome for intermediate-risk rhabdomyosarcoma: a report from the … DS Hawkins, YY Chi, JR Anderson, J Tian, CAS Arndt, L Bomgaars, ... Journal of Clinical Oncology 36 (27), 2770-2777, 2018 | 155 | 2018 |
| Bisphosphonates in orthopaedic surgery CD Morris, TA Einhorn JBJS 87 (7), 1609-1618, 2005 | 153 | 2005 |
| Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors E Palmerini, EL Staals, RG Maki, S Pengo, A Cioffi, M Gambarotti, P Picci, ... European Journal of Cancer 51 (2), 210-217, 2015 | 141 | 2015 |
| Allograft-prosthesis composite reconstruction of the proximal part of the humerus: functional outcome and survivorship A Abdeen, BH Hoang, EA Athanasian, CD Morris, PJ Boland, JH Healey JBJS 91 (10), 2406-2415, 2009 | 139 | 2009 |
| Bone cancer JS Biermann, DR Adkins, M Agulnik, RS Benjamin, B Brigman, ... Journal of the National Comprehensive Cancer Network 11 (6), 688-723, 2013 | 136 | 2013 |
| Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate D Goodman, E Pamer, A Jakubowski, C Morris, K Sepkowitz Clinical Infectious Diseases 35 (3), e35-e36, 2002 | 122 | 2002 |
| Poly(anhydride) administration in high doses in vivo: Studies of biocompatibility and toxicology C Laurencin, A Domb, C Morris, V Brown, M Chasin, R McConnell, ... Journal of biomedical materials research 24 (11), 1463-1481, 1990 | 118 | 1990 |
| Pediatric osteogenic sarcoma HJ Kim, PN Chalmers, CD Morris Current opinion in pediatrics 22 (1), 61-66, 2010 | 107 | 2010 |
| Compress® knee arthroplasty has 80% 10-year survivorship and novel forms of bone failure JH Healey, CD Morris, EA Athanasian, PJ Boland Clinical Orthopaedics and Related Research® 471 (3), 774-783, 2013 | 94 | 2013 |
| Prospective identification of risk factors for wound infection after lower extremity oncologic surgery CD Morris, K Sepkowitz, C Fonshell, N Margetson, J Eagan, J Miransky, ... Annals of surgical oncology 10, 778-782, 2003 | 87 | 2003 |
| Early equivalence of uncemented press-fit and Compress® femoral fixation GL Farfalli, PJ Boland, CD Morris, EA Athanasian, JH Healey Clinical Orthopaedics and Related Research® 467 (11), 2792-2799, 2009 | 86 | 2009 |
| Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA M Hayashi, D Chu, CF Meyer, NJ Llosa, G McCarty, CD Morris, AS Levin, ... Cancer 122 (19), 3015-3023, 2016 | 75 | 2016 |
| Local control for intermediate-risk rhabdomyosarcoma: Results from D9803 according to histology, group, site, and size: A report from the Children's Oncology Group SL Wolden, ER Lyden, CA Arndt, DS Hawkins, JR Anderson, ... International Journal of Radiation Oncology* Biology* Physics 93 (5), 1071-1076, 2015 | 70 | 2015 |
